Endometriosis is an often painful disorder in which tissue similar to the tissue that normally lines the inside of your uterus. Recent data from the U.S. suggest that the prevalence of endometriosis ranges from 6.6 to 16.2%. Symptoms of endometriosis vary from woman to woman. Some experience pelvic pain only during their menstrual period. Other women feel pain in their lower back and abdominal regions. In many cases, endometriosis is a chronic condition that requires treatment to control symptoms. Those with endometriosis often experience pain during bowel movement and urination. The condition is often accompanied by excess bleeding, especially during the menstrual cycle.
Endometriosis treatment involves laparoscopy, a simple surgical procedure in which a thin tube with a camera is inserted into the abdomen and pelvic cavity. This procedure helps a doctor identify patches of endometriosis tissue. The diagnosis is not possible without this procedure, but many women experience pain even before it is confirmed by laparoscopy. Other treatments may include hormone therapy, painkillers, and intrauterine devices.
The symptoms of endometriosis can be very severe and affect the ability to conceive. During your first consultation, your doctor will discuss your symptoms, health history, and family medical history. A pelvic exam may also be done, to determine if you have the disease. During a laparoscopy, the doctor can visualize your endometriosis and perform a biopsy. Once the diagnosis is made, you can select between pain medications and surgery to remove the affected endometrial tissue.
The World Health Organization has recognized the importance of endometriosis and the impact that it has on a woman’s quality of life and fertility. Through partnerships with a variety of stakeholders, including non-state organizations and patients, W.H.O is working to increase awareness and improve endometriosis treatment and care. By publishing articles about endometriosis and collecting stories about the condition, the organization is helping to increase understanding of the disorder.
According to Coherent Market Insights, the increasing research activities for development of new drugs for the global endometriosis treatment market is expected to be a major driver for growth of the market over the forecast period. For instance in 2017, AbbVie, biopharmaceutical company in co-operation with Neurocrine Biosciences Inc submitted New Drug Application (NDA) to the U.S. Food and drug Administration (FDA) for a new drug named elagolix. It is an orally administering gonadotropin releasing hormone antagonist, which is being evaluated for management of pain associated with endometriosis.
Other factors such as increase in prevalence of endometriosis, robust pipeline, awareness about endometriosis is expected to support endometriosis treatment market growth. For instance, Triptoreline sponsored by University Hospital, Rouen is in Phase 3 Clinical Trials; Triptoreline cures deep endometriosis in the rectum , Myovant Sciences has Relugolix in phase 3 Clinical Trials; Relugolix ceases non-menstrual pelvic pain, Indocyannine Green sponsored by University Hospital in Phase 4 Clinical Trials; Indocyannine Green treats recto vaginal endometriosis, Dienogest sponsored by the University Of Hong Kong is in Phase 4 Clinical Trials; dienogest stops the reoccurance of endometriosis cyst, Merional sponsored by Cario University is in phase 3 Clinical Trials; Merional controls intrauterine insemination cycles in women having endometriosis.
